Tektonyx is harnessing the power of site-selected click conjugation to generate first-in-class drug conjugates. Our clinically validated proprietary SSO platform enables flexible conjugation of cytotoxins, radioisotopes, oligos and degraders to small proteins at high levels of payload density (DAR). The company is currently developing a pipleine of small protein ADCs with dual-payloads and bispecific targeting.